CoChat

Diagnosis and treatment of COVID-19 associated pulmonary apergillosis in critically ill patients: results from a European confederation of medical mycology registry

Open access
Prattes, Juergen, Wauters, Joost, Giacobbe, Daniele Roberto, Lagrou, Katrien, Hoenigl, Martin, on behalf of the ECMM-CAPA Study Group, Koehler, Philipp, Salmanton-García, Jon, Rautemaa-Richardson, Riina, Hatzl, Stefan, Maertens, Johan, Debaveye, Yves, Bourgeois, Marc, Reynders, Marijke, Rutsaert, Lynn, Van Regenmortel, Niels, Lormans, Piet, Feys, Simon, Reisinger, Alexander Christian, Cornely, Oliver A, Lahmer, Tobias, Valerio, Maricela, Delhaes, Laurence, Jabeen, Kauser, Steinmann, Joerg, Chamula, Mathilde, Bassetti, Matteo · 2021 · Intensive Care Medicine
Cited by 56

The DOI matches its Crossref record.

Abstract

Dear Editor, Coronavirus disease 2019 (COVID-19)-associated pulmonary aspergillosis (CAPA) has emerged as an important complication among patients with acute respiratory failure caused by SARS-CoV-2 [1–3]. A cornerstone in CAPA diagnosis is microbiology, including culture from lower respiratory tract samples, and bronchoalveolar lavage fluid (BALF) galactomannan (GM) [4, 5]. We performed a multinational cohort study including 20 centers in 9 countries with the aim to evaluate diagnostic approaches and treatment of CAPA as well as CAPA prevalence. All participating centers were invited to provide data on diagnostic work-up, treatment and outcome on prospective cohorts of consecutive COVID19 ICU patients (inclusion criteria: SARS-CoV-2-positive polymerase chain reaction, admission to intensive care unit (ICU) due to respiratory failure) with and without CAPA via an online case report form between 03/2020 and 05/2021. Cases were then classified according to the 2020 ECMM/ISHAM consensus criteria [4]. The study protocol was approved by the Medical University of Graz (EC #32–296 ex 19/20) and the other participating centers. A total of 592 cases were entered (98.5% from Europe; for demographics see Supplementary Table 1) of whom 11 (1.9%) had proven CAPA, 80 (13.5%) probable CAPA and 18 (3%) possible CAPA. Table 1 displays diagnostic characteristics of those with CAPA. Median BALF-GM optical density index (ODI) in 83 CAPA patients was 2.74 (IQR 1.70–5.78). BALF-GM ODI > 1.0 was also reported in 4/170 (2.4%) patients without CAPA. BALF culture growing Aspergillus was detected exclusively among CAPA patients (0/184 non-CAPA patients). Serum GM was positive (> 0.5 ODI) in 1/192 patients without CAPA (0.5%). Antifungal treatment details are depicted in Table 1. Among those receiving systemic antifungal treatment, 52% were alive at ICU discharge. During a median observation time of 32 days, 261 ICU deaths were observed. This corresponded to an − 30, − 60 and − 90 day ICU mortality of 36% (95% CI 33–40), 46% (95% CI 42–51) and 49% (95% CI 44–53). By applying a Fine-Gray competing risk model the 109 diagnosed CAPA cases (i.e., possible, probable or proven) on ICU corresponded to an − 1, − 15and − 90 day ICU CAPA rate of 1% (95% CI 1–3), 16% (95% CI 13–20) and 20% (95% CI 16–32) (Supplementary Fig. 1). Overall CAPA prevalence in our cohort was 15.4% and, therefore, within the range that has been previously reported in the literature [5], although prevalence varied widely between centers. Several factors such as awareness, diagnostic algorithms, local epidemiology and socioeconomic factors may explain these differences. *Correspondence: joost.wauters@uzleuven.be; hoeniglmartin@gmail. com 1 Division of Infectious Diseases, Excellence Center for Medical Mycology (ECMM), Medical University of Graz, Graz, Austria 2 Medical Intensive Care Unit, Excellence Center for Medical Mycology (ECMM), University Hospitals Leuven, Leuven, Belgium Full author information is available at the end of the article

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00134-021-06471-6

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

Metadata

Authors
Prattes, J., Wauters, J., Giacobbe, D. R., Lagrou, K., Hoenigl, M., on behalf of the ECMM-CAPA Study Group, Koehler, P., Salmanton-García, J., Rautemaa-Richardson, R., Hatzl, S., Maertens, J., Debaveye, Y., Bourgeois, M., Reynders, M., Rutsaert, L., Van Regenmortel, N., Lormans, P., Feys, S., Reisinger, A. C., Cornely, O. A., Lahmer, T., Valerio, M., Delhaes, L., Jabeen, K., Steinmann, J., Chamula, M., & Bassetti, M.
Venue
Intensive Care Medicine
Published
2021-07-16
Volume
47
Issue
10
Pages
1158-1160
ISSN
  • 0342-4642 (ISSN-L)
  • 1432-1238
OpenAlex
W3177696589
Cited by
56
References
0
FWCI
3.55
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.